Señales en vivo de TLSA | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (20 may 2024 @ 16:00):

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology...

Stats
Volumen de hoy	183 715
Volumen promedio	196 269
Capitalización de mercado	78.75M
EPS	$0 ( 2024-04-22 )
Próxima fecha de ganancias	( $0 ) 2024-05-27
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.53
ATR14	$0.0160 (2.08%)

Volumen Correlación

Largo: 0.25 (neutral)

Corto: -0.20 (neutral)

Signal:(48.83) Neutral

Tiziana Life Sciences PLC Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas
FITBP	-0.876
ACGLN	-0.87
PFF	-0.853
ENLV	-0.842
RCEL	-0.838
JSM	-0.837
ADSK	-0.827
FITBO	-0.814
FTXH	-0.811
BJK	-0.806

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Tiziana Life Sciences PLC Correlación - Moneda/Commodity

0.74
( moderate )

0.00
( neutral )

0.67
( moderate )

0.70
( moderate )

-0.74
( moderate negative )

Tiziana Life Sciences PLC Finanzas

Annual	2022
Ingresos:	$0
Beneficio Bruto:	$-51 000.00 (0.00 %)
EPS:	$-0.160

FY	2022
Ingresos:	$0
Beneficio Bruto:	$-51 000.00 (0.00 %)
EPS:	$-0.160

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-0.139

FY	2020
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-0.120

Financial Reports:

No articles found.

Tiziana Life Sciences PLC Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Tiziana Life Sciences PLC

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.